Abstract Details

Title Clinical and Demographic Variations and Health Outcomes of Neurocognitive Impairment in Neurosarcoidosis

Topic Autoimmune Neurology

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 2-003

Objective To investigate demographic, clinical, diagnostic, and prognostic factors associated with Neurocognitive Impairment (NCI) in patients with Neurosarcoidosis (NS).

Background Neurocognitive impairment (NCI) is a poorly understood yet disabling manifestation of NS, often under-recognized due to overlap with psychiatric comorbidities. Prior studies have not characterized the clinical and prognostic features associated with NCI in NS patients.

Design/Methods This retrospective chart review examined patients with probable or definite NS treated between 2010 and 2025. NCI was defined using MMSE and MOCA scores, developing after initial NS diagnosis. Analyses were done using IBM SPSS, with Pearson Chi-Square and ANOVA statistical tests.

Results NCI was present in 32/83 patients (38.6%) with NS. Compared with NS patients without NCI, those with NCI were more likely to present with seizures (NCI = 34.4% vs non-NCI = 11.8%; n=11 vs n=6; p = .042), male sex (NCI = 59.4% vs non-NCI = 29.4%; n=19 vs n=15; p = .023), psychiatric symptoms (NCI = 56.3% vs non-NCI = 35.3%; n=18 vs n=18; p = .041), and headaches (NCI = 56.3% vs non-NCI = 31.4%; n=18 vs n=16; p = .039). NCI patients also had higher rates of elevated CSF protein >45 mg/dL (NCI = 51.5% vs non-NCI = 20%; n=17 vs n=9; p = .0069), and higher CSF RBC counts (median NCI = 11 vs non-NCI = 2; p = .009). Malignancies were significantly less common among NCI patients (NCI = 3.1% vs non-NCI = 21.6%; n=1 vs n=11; p = .020). Finally, outcomes analysis demonstrated increased hospitalizations among patients with NCI (NCI = 1.43 vs non-NCI = 0.68; p = .012).

Conclusions NS patients with NCI exhibit a distinct clinical phenotype marked by male predominance, higher seizure and psychiatric symptom burden, elevated CSF markers, and increased healthcare utilization, underscoring the need for early recognition. Further studies are necessary to confirm validity.

Authors/Disclosures
Amritaa R. Thalla, MD, MBBS PRESENTER	Dr. Thalla has nothing to disclose.
Tanisha Sanganeria, MBBS	Dr. Sanganeria has nothing to disclose.
Laya Rao (Villas at Hermann Park)	Ms. Rao has nothing to disclose.
Filemon C. Tan III, BS	Mr. Tan has nothing to disclose.
Rajesh K. Gupta, MBBS (UTHealth)	Dr. Gupta has nothing to disclose.